James Paul Scopa's Net Worth

$212 Million

Who is James Paul Scopa?

James Paul Scopa has an estimated net worth of $212 Million. This is based on reported shares across multiple companies, which include Radius Health, Inc., Pacira Pharmaceuticals, Inc., MEMORY PHARMACEUTICALS CORP, PEPLIN INC, TriVascular Technologies, Inc., DICE Therapeutics, Inc., Verastem, Inc., Syndax Pharmaceuticals Inc, Adverum Biotechnologies, Inc., Aligos Therapeutics, Inc., ARATANA THERAPEUTICS, INC., Conatus Pharmaceuticals Inc, Epizyme, Inc., Cerecor Inc., and CHIASMA, INC.

SEC CIK

James Paul Scopa's CIK is 0001356950

Past Insider Trading and Trends

2014 was James Paul Scopa's most active year for acquiring shares with 16 total transactions. James Paul Scopa's most active month to acquire stocks was the month of January. 2014 was James Paul Scopa's most active year for disposing of shares, totalling 12 transactions. James Paul Scopa's most active month to dispose stocks was the month of January. 2013 saw James Paul Scopa paying a total of $12,500,007.27 for 17,154,443 shares, this is the most they've acquired in one year. In 2013 James Paul Scopa cashed out on 14,314,805 shares for a total of $13,930,000.00, their largest year based on trade value.